Consensus TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
13.47 ^USD	-3.16%		-2.25%	-21.14%

Apr. 18	Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	MT
Apr. 18	Sector Update: Health Care	MT

Evolution of the average Target Price on TG Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b5f8edfb439e8826cdf55260b1e.WgOwwugamue2k-hjXnWCVlyhXjk7Wbycj7bYYQPDp6M.F2zD9Nst7NCFpZs1ERLrEjbrJn1iHfv558eyCk26wu4paYj63GPyt87GvQ~956e4c623691c032f1a9d488cb3bfe31

Analyst Recommendations on TG Therapeutics, Inc.

TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	Apr. 18	MT
Goldman Sachs Raises Price Target on TG Therapeutics to $13 From $12, Maintains Neutral Rating	Feb. 29	MT
B. Riley Adjusts Price Target on TG Therapeutics to $29 From $24, Maintains Buy Rating	Feb. 05	MT
HC Wainwright Adjusts TG Therapeutics Price Target to $45 From $41, Maintains Buy Rating	Jan. 11	MT
B. Riley Adjusts Price Target on TG Therapeutics to $24 From $32, Keeps Buy Rating	23-10-20	MT
JPMorgan Cuts TG Therapeutics Price Target to $22 From $34, Maintains Overweight Rating	23-08-07	MT
Goldman Sachs Upgrades TG Therapeutics to Neutral From Sell, Adjusts Price Target to $12 From $16	23-08-02	MT
B. Riley Lowers TG Therapeutics' PT to $32 From $42 After Lower-Than-Expected Q2 Results, Keeps Buy Rating	23-08-02	MT
HC Wainwright Adjusts TG Therapeutics' Price Target to $41 From $34, Keeps Buy Rating	23-08-01	MT
Goldman Sachs Adjusts TG Therapeutics' Price Target to $16 From $10, Keeps Sell Rating	23-07-24	MT
Ladenburg Thalmann Raises Price Target on TG Therapeutics to $37.50 From $26, Maintains Buy Rating	23-05-02	MT
B. Riley Raises TG Therapeutics' Price Target to $42 From $39 After 'Strong' Q1 Results, Keeps Buy Rating	23-05-02	MT
HC Wainwright Adjusts Price Target on TG Therapeutics to $28 From $24, Reiterates Buy Rating	23-04-14	MT
B. Riley Raises TG Therapeutics' Price Target to $39 From $23, Keeps Buy Rating	23-04-11	MT
Cantor Fitzgerald Raises Price Target on TG Therapeutics to $24 From $18, Maintains Overweight Rating	23-02-07	MT
Evercore ISI Adjusts Price Target on TG Therapeutics to $25 From $16, Maintains Outperform Rating	23-01-24	MT
Evercore ISI Adjusts Price Target on TG Therapeutics to $16 From $11, Maintains Outperform Rating	22-12-30	MT
Goldman Sachs Adjusts Price Target on TG Therapeutics to $6 From $4, Maintains Sell Rating	22-12-30	MT
B. Riley Boosts Price Target on TG Therapeutics to $23 From $17, Keeps Buy Rating	22-12-30	MT
BofA Raises Price Target on TG Therapeutics to $6 From $5, Maintains Underperform Rating	22-12-29	MT
HC Wainwright Boosts Price Target on TG Therapeutics to $24 From $19, Maintains Buy Rating	22-12-29	MT
B. Riley Lowers TG Therapeutics' Price Target to $17 from $23, Notes Market Size/Growth Dynamics; Reiterates Buy Rating	22-06-13	MT
TG Therapeutics' Shares Plummet After BofA Securities Initiates Coverage at Underperform	22-05-20	MT
BofA Securities Starts TG Therapeutics at Underperform With $5 Price Target	22-05-20	MT
B. Riley Lowers TG Therapeutics' PT to $23 from $35, Says Exit from Oncology 'Disappointing'; Keeps Buy Rating	22-04-19	MT